Posted: 20 November 2024 A single dose may reduce compulsive behaviours in mice Research at The Florey suggests the psychedelic compound psilocybin has potential to treat obsessive-compulsive disorder (OCD) and related disorders. The study – led by Florey…
Posted: 20 November 2024 The Albanese Government is establishing a new national body to provide leadership, coordination and expertise so all Australians can reap the benefits of cutting-edge genomic research and technologies. Genomics Australia will help fight cancers,…
Posted: 20 November 2024 WEHI researchers have found a new way to predict a subset of patients who are likely to become resistant to PARP inhibitors (PARPi), a key therapy used to treat ovarian and breast cancers in…
Posted: 20 November 2024 Two esteemed researchers have been appointed to lead the Colonial Foundation Diagnostics Centre, a landmark research centre working to enhance precision diagnosis for inflammatory diseases. The centre, co-led by WEHI and the Royal Melbourne Hospital…
Posted: 20 November 2024 Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will initially focus on…
Posted: 20 November 2024 We have undertaken a national audit of Australia’s health and medical research workforce. You can now read our findings and learn about opportunities to support our researchers into the future. We carried out the…
Posted: 19 November 2024 To increase awareness of the breadth of career pathways available across the health and medical research sector, BioMelbourne Network is kicking-off a one-year project to develop a central portal containing a suite of workforce…
Posted: 14 November 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial…
Posted: 14 November 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio. A research collaboration agreement between the…
Posted: 14 November 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has entered…
Posted: 14 November 2024 A team of researchers has for the first time cured patients with a lethal skin disease, in a breakthrough study that could lead to an approved curative therapy for the deadly condition. Toxic epidermal…
Posted: 14 November 2024 Associate Professor Sarah Jones from the School of Clinical Sciences at Monash Health is one of five researchers worldwide and the only Australian researcher to receive an inaugural Translational Bridge Award from the Lupus Research Alliance (LRA) in New…